EMA concludes review of weight management medicine Mysimba
EMA concludes review of weight management medicine Mysimba
EMA concludes review of weight management medicine Mysimba
Summary of opinion: Pemazyre, 27/03/2025 Negative
Summary of opinion: Bosulif, 27/03/2025 Positive
Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) 1 April 2025
Policy 85: Identity and Access Management to EMA IT Systems
Quarterly System Demo - Q1 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2025, 09:00 (CET) to 26 March 2025, 11:30 (CET)
Human medicines European public assessment report (EPAR): Respreeza, alpha1-proteinase inhibitor (human), Date of authorisation: 20/08/2015, Revision: 15, Status: Authorised
Product Management Service (PMS) webinar : Unlocking Integration – MAH & Software Developers to explore PMS API Machine-to-Machine Connection, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 March 2025, 10:00 (CET) to 14 March 2025, 12:00 (CET)
Human medicines European public assessment report (EPAR): VeraSeal, human fibrinogen,human thrombin, Date of authorisation: 10/11/2017, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Febuxostat Krka, febuxostat, Date of authorisation: 28/03/2019, Revision: 7, Status: Authorised